Warren Buffett has given more interviews than almost anyone alive, and for two decades he has kept choosing the same microphone. Becky Quick gets to Squawk Box before four in the morning, reads more annual reports than most fund managers, and has spent a career being the person the world’s richest investors actually talk to.
In January 2026 she used all of that trust for something else entirely. This is the story of both: the anchor Buffett calls, and the cause she decided to make public — which, by September 2026, had a clinical trial authorised in the UK behind it.
Last updated: 26 October 2026.
| Role | Co-anchor, CNBC’s Squawk Box, weekdays 6am to 9am ET. Also co-anchors On the Money |
| Born | 18 July 1972, Gary, Indiana |
| Brought up | Her father was a geologist, and oil-production booms moved the family through Indiana, Ohio, Texas and Oklahoma before they settled in Medford, New Jersey |
| Education | Rutgers University, BA Political Science, 1993 — editor-in-chief of The Daily Targum and a Times Mirror Fellow |
| Before CNBC | Seven years at The Wall Street Journal from 1994; covered retail and e-commerce, helped launch the paper’s website in April 1996, then international news editor |
| Joined CNBC | 2001, as a financial correspondent |
| Known for | Warren Buffett interviews, and launching CNBC Cures on 8 January 2026 |
Biographical record and CNBC’s own reporting. Verified 26 October 2026.
What this article covers
- The alarm nobody envies
- A student editor in New Jersey
- Seven years at the Wall Street Journal
- The Buffett beat, and why access is the story
- October 2015: the debate
- January 2026: the story she chose to tell
- Why rare diseases need that power
- The trial, stated precisely
- A note on her family and the numbers
- Corrections made to this page
- Frequently asked questions
The Alarm Nobody Envies
Squawk Box goes on air at six in the morning, which means Becky Quick’s day starts in the dark, hours earlier, with overnight markets, corporate results and whatever broke in Asia while America slept. She has done that shift for two decades.
Morning business television is the most punishing job in the genre and the most valuable, because the audience is traders, executives and anyone whose money moves before breakfast — and they do not forgive a host who has not read the filing. Everything else here grew out of that daily discipline.
A Student Editor in New Jersey
The path started at Rutgers University, where Quick read political science, graduated in 1993, and ran the student paper The Daily Targum as editor-in-chief. She also held a Times Mirror Fellowship from the university’s Journalism Resources Institute.
Anyone who has done the student-editor job knows what it actually teaches: how to fill a paper when half the writers vanish, how to defend a story to angry people, and how to work to a deadline that does not care about your exams. No finance degree, no Wall Street internship — just a young editor who learned to report first and specialise later. Her father was a geologist, and oil booms had already moved the family through Indiana, Ohio, Texas and Oklahoma before they settled in Medford, New Jersey.
Seven Years at the Wall Street Journal
In 1994 she joined The Wall Street Journal, the most demanding classroom in business journalism, and covered retail and e-commerce just as those beats turned into the biggest story on earth. She then helped launch the paper’s website, which went live in April 1996, and served as its international news editor.
Consider that combination in the mid-nineties: a young reporter covering the internet who was also building one of the first great news websites. She was inside the disruption she was assigned to explain, which is the best possible preparation for everything since.
After seven years in print she joined CNBC in 2001 as a financial correspondent, arriving just in time for the dot-com wreckage she had spent the boom covering. Print reporters do not always survive television — the skills look similar and are not — but she already knew the companies, the executives and the numbers.
The Buffett Beat, and Why Access Is the Story
Somewhere in those years, Becky Quick became the journalist Warren Buffett talks to. She has interviewed him repeatedly across two decades, hosted the 2007 documentary Warren Buffett: The Billionaire Next Door Going Global, and anchored CNBC’s coverage from Berkshire Hathaway’s annual meeting, the Omaha weekend that draws tens of thousands of investors.
Access like that is not given for charm; it is earned by never misrepresenting what somebody said. Her list beyond Buffett tells the same story: Bill Gates, Charlie Munger, Jamie Dimon, Alan Greenspan, T. Boone Pickens, and three American presidents.
It is worth being precise about what that means, because it is the rarest currency in financial journalism. When a chief executive picks an interviewer, they are choosing who gets to shape the first draft of their news — and the ones chosen repeatedly are the ones who ask hard questions fairly. Her Berkshire and Davos bookings, the Fortune column, the prime-time specials, all descend from that reputation, built one careful interview at a time.
October 2015: The Debate
Her profile broke out of business news entirely on 28 October 2015, when she co-moderated a Republican presidential primary debate for CNBC alongside Carl Quintanilla and John Harwood.
Debate moderation is journalism’s highest-wire act: live, hostile, watched by tens of millions, with every question dissected for days afterwards. That night became one of the most argued-about debates of the cycle, and it placed her permanently in the small group of business journalists trusted with national political stages.
January 2026: The Story She Chose to Tell
Image source: pexels.com
On 8 January 2026 Quick did something no anchor is obliged to do. She published her own account of her family’s rare disease journey and spoke about it on NBC’s Today: her daughter Kaylie lives with SYNGAP1, a rare genetic condition in which the body produces only about half the SynGAP protein a developing brain needs.
Diagnosis came through genetic testing just before Kaylie turned three, after years of early intervention and unanswered questions. Quick has said the variant was de novo — a single letter of DNA altered at birth, not inherited from either parent. She told it, by her own account, so that other families would not feel as alone as hers had.
The disclosure came with something built to outlast it. The same day, CNBC launched CNBC Cures, an initiative to raise awareness and build community around rare diseases — a category the network describes as touching roughly 30 million Americans. In March 2026 Quick hosted a half-day CNBC Cures summit in New York, moderating discussions with researchers, doctors and advocates.
It is an unusual move for a markets anchor and a very logical one: she took the convening power that gets billionaires on a stage and pointed it at families who have nobody convening for them.
Why Rare Diseases Need That Power
The arithmetic behind the initiative explains its urgency, and it is worth seeing rather than being told.
CNBC puts the figure at roughly 30 million; the US resident population was 341,784,857 at 1 July 2025 per the US Census Bureau. Figures in millions.
That is the paradox of the field. Individually, these conditions are vanishingly rare — collectively they affect close to one American in eleven. Rare conditions attract little research money, few specialists and almost no public attention, while adding up to a population larger than most countries.
CNBC, 6 August 2026 — just over 1,800 people identified globally, a first trial enrolling at least 30 children, and no approved disease-modifying treatments. All three are counts of people or products.
Note how the diagnosed figure moves. Quick said “around 1,700 or so” in January 2026; by 6 August 2026 CNBC reported just over 1,800. That rise is not the disease spreading — it is diagnosis catching up, which is precisely what awareness campaigns are for. This page previously gave 1,700 as a current figure three times over; it was correct in January and is now dated.
The Trial, Stated Precisely
In August 2026 came the kind of update this beat rarely gets. But the previous version of this page said a treatment had been “advanced into human trials”, and that overstates what has happened — a distinction that matters a great deal if you are a parent reading it.
| Item | The position | Source |
|---|---|---|
| The candidate | CMP-002, from CAMP4 Therapeutics | CNBC, 6 Aug 2026 |
| Australia | TGA and ethics clearance, 27 July 2026 | CAMP4 release |
| Argentina | ANMAT clearance | CAMP4 releases |
| United Kingdom | Phase 1/2 authorisation, 10 September 2026 | CAMP4 releases |
| Trial design | Double-blind, placebo-controlled, enrolling at least 30 children aged 2–18 | CNBC |
| When it starts | Initiation anticipated in Q4 2026, per the company’s 13 August 2026 quarterly report | SEC filing |
| Existing treatments | None. There are no approved disease-modifying treatments for SYNGAP1 | CNBC |
CAMP4 Therapeutics releases, its SEC filing and CNBC reporting. Accurate as at 26 October 2026.
Regulatory clearance is not a trial under way, and an early-phase trial is not a treatment. As at CAMP4’s 13 August 2026 quarterly report, initiation was anticipated in Q4 2026. Nothing about a Phase 1/2 study is a promise of anything, and this page will not imply otherwise. Anyone affected should speak to a clinician, not act on a news page.
For a UK reader, the important line is the third one in that table. The UK authorised the Phase 1/2 study on 10 September 2026 — which means a condition with roughly 1,800 diagnosed people worldwide now has a trial cleared to run in Britain. For a community that size, that is genuinely historic, and it arrived in the same year as the awareness campaign.
The Squawk Box Institution
Through all of it, the day job never stopped. Squawk Box remains the programme that sets the American market’s morning conversation, and Quick has anchored it through the financial crisis, the pandemic crash, the meme-stock strangeness and the artificial intelligence boom — alongside a rotating cast of co-hosts and one constant: the six o’clock start.
This series has profiled the specialists around her — Pippa Stevens on energy, Diana Olick on housing, Sara Eisen and Dominic Chu on markets — and the morning show is where their reporting usually lands first. The investors who appear on it get the same treatment: see Bryn Talkington and Mario Gabelli.
Her arc invites one obvious comparison: Maria Bartiromo, who spent twenty years at CNBC before leaving for Fox. Both women came up in the same era, both broke into rooms that were not built for them, and both became the interview their industry’s biggest names accepted. They took opposite roads afterwards — one into politics and one deeper into the markets beat — which is exactly what makes reading the two careers side by side instructive. For a third path out of news and into opinion, there is Megyn Kelly.
A Note on Her Family and the Numbers
This article covers Becky Quick’s family only as far as she herself made it public — in her own CNBC piece, on national television, and through an initiative she launched — and no further, because the rest belongs to her household rather than to search engines.
No net worth or salary figure appears here either. Network contracts are confidential and the numbers circulating online are invented. The previous version of this page promised readers a “separate guide to what American anchors actually earn” — no such guide exists on this site, so that cross-reference has been removed rather than left dangling.
Doing the Job Nobody Wants
Her own advice remains the neatest summary of the career: do the jobs nobody else wants to do. Nobody wanted the four a.m. shift, and it made her the voice of the market’s morning. Nobody wanted to be the print reporter learning television at thirty, and it made her the interviewer investors trust.
And nobody wants to talk publicly about a child’s diagnosis — which is exactly why she did, and why a community of roughly 1,800 diagnosed people worldwide now has a national platform it did not have in 2025, and a trial cleared in three countries.
Corrections Made to This Page
| What it said | Why it changed |
|---|---|
| No external links or sources at all | The disclaimer named CNBC, Wikipedia and “published interviews” but gave not one URL, on a page full of dates and figures. Every number now carries a source |
| “CAMP4 had advanced a treatment into human trials” | Overstated. CAMP4 secured regulatory clearance (Australia 27 Jul 2026, Argentina, UK 10 Sep 2026) and expected initiation in Q4 2026. Clearance is not a trial under way |
| No mention of the UK at all | The UK Phase 1/2 authorisation of 10 September 2026 is the most relevant fact here for a British reader, and it was missing |
| “roughly 1,700 diagnosed worldwide”, three times, as current | That was Quick’s own January 2026 figure. CNBC reported just over 1,800 on 6 August 2026. Both now given with dates |
| “at the start of this year”, “this week”, “only hours earlier” | Time-relative phrasing that rots. All made absolute |
| A promised guide to “what American anchors actually earn” | No such page exists on this site. The dangling cross-reference is gone |
| Raw HTML headings, no Gutenberg blocks | The whole article had a wp: block count of zero. Rebuilt as proper blocks |
| No structured data | FAQ JSON-LD added |
| Vague biography detail | Named properly: The Daily Targum, the Times Mirror Fellowship, On the Money, the 2007 documentary title, and the April 1996 website launch |
All corrections made on 26 October 2026. The image and all original links were kept. The page’s refusal to publish a net worth, and its limits on family coverage, were deliberate and have been preserved.
Frequently Asked Questions
Who is Becky Quick?
Co-anchor of CNBC’s Squawk Box and On the Money, a former Wall Street Journal reporter who joined CNBC in 2001 and is best known for two decades of Warren Buffett interviews.
Why does Warren Buffett give interviews to Becky Quick?
She has interviewed him repeatedly across two decades and anchors CNBC’s Berkshire Hathaway annual meeting coverage. Access like that is earned by asking hard questions fairly and quoting people accurately, which is the whole currency of the job.
What is CNBC Cures?
An initiative CNBC launched on Thursday 8 January 2026 to raise awareness and build community around rare diseases — a category it describes as affecting around 30 million Americans. Quick hosted a half-day summit in New York in March 2026.
What is SYNGAP1?
A rare genetic disorder in which the body produces only about half the SynGAP protein a developing brain needs. Quick has said her daughter Kaylie’s variant was de novo — a single letter of DNA altered at birth, not inherited from either parent.
How many people have SYNGAP1?
Just over 1,800 worldwide had been identified by August 2026, according to CNBC. Quick put it at “around 1,700 or so” in January 2026. The number rises as genetic testing spreads — which is part of the point: many families are still undiagnosed.
Is there a treatment for SYNGAP1 yet?
No approved one. But CAMP4 Therapeutics has cleared regulators in Australia, Argentina and the UK to run a Phase 1/2 trial of CMP-002, and said in August 2026 that it expected to begin in Q4 2026. Regulatory clearance is not a trial under way, and an early trial is not a treatment.
Is the trial happening in the UK?
The UK authorised it on 10 September 2026 — which, on a British site, is the most relevant part of this story and was missing from the previous version of this page. Anyone affected should raise it with a clinician rather than acting on a news page.
Where did Becky Quick work before CNBC?
The Wall Street Journal, for seven years from 1994, covering retail and e-commerce. She helped launch the paper’s website in April 1996 and was its international news editor.
What debate did she moderate?
She co-moderated the Republican presidential primary debate on 28 October 2015 for CNBC, with Carl Quintanilla and John Harwood. It became one of the most argued-about debates of the cycle.
What is Becky Quick’s net worth?
Not documented, and this page will not invent one. Network contracts are confidential and the figures circulating online have no source behind them.
What is her advice on building a career?
Her own line, given to CNBC’s readers: do the jobs nobody else wants to do. Nobody wanted the pre-dawn shift, and it made her the voice of the market’s morning.
Final Thoughts
A student editor from Rutgers who learned the internet at the Wall Street Journal, mastered the morning shift at CNBC, and became the reporter Warren Buffett keeps calling back. Then, in 2026, Becky Quick spent that hard-won trust on families nobody was covering.
Careers in business news are usually measured in ratings and bookings. Hers is starting to be measured in regulatory clearances — three of them this year, including one in the UK, for a condition that had none when she started talking about it.
Sources
- CNBC — Becky Quick details her daughter’s rare disease journey (8 January 2026)
- TV Insider — Quick discusses Kaylie’s diagnosis on NBC’s Today
- Inside Precision Medicine — Becky Quick on rare diseases and CNBC Cures
- CNBC — CAMP4 advances a SYNGAP1 treatment towards human trials (6 August 2026)
- CAMP4 Therapeutics — Australian regulatory clearance for CMP-002 (27 July 2026)
- CAMP4 Therapeutics — news releases, including UK authorisation (10 September 2026)
- CAMP4 Therapeutics — Q2 2026 results, SEC Form 8-K (13 August 2026)
- US Census Bureau — population estimates (341,784,857 at 1 July 2025)
- Rebecca Quick — biographical record
Disclaimer
Career facts are drawn from CNBC’s reporting, the biographical record and published interviews, all linked above. The family and health information here is reported only as Becky Quick has made it public herself, through CNBC, NBC’s Today and the CNBC Cures initiative. Nothing in this article is medical or financial advice. Regulatory clearance for a clinical trial is not a treatment, and early-phase trials carry no guarantee of outcome — anyone affected should speak to a clinician. Net worth figures circulating online are unverified and excluded. Information correct as at 26 October 2026. More from The UK Post.